NLM-001

DRUG2 trials

Sponsors

Nelum Corp

Conditions

Advanced Pancreatic CancerPancreatic Ductal AdenocarcinomaUntreated

Phase 1

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Active, not recruitingNCT04827953

Nelum CorpPancreatic Ductal Adenocarcinoma

Start: 2021-09-01End: 2025-04-30Updated: 2024-12-30

Phase 2

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Not yet recruitingNCT07578337

Nelum CorpAdvanced Pancreatic Cancer, Untreated

Start: 2026-07-15End: 2029-02-28Target: 40Updated: 2026-05-13

Related Papers

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial

2025-12-15

Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.

2022-11-24186 citations